Monday, June 15, 2026

North Korea Sends Top Official to China Treaty Banquet, Hinting at Warmer Ties

North Korea celebrates the China-North Korea Friendship Treaty, indicating improved relations and strategic cooperation between the two nations.

Who is Choi Il-hwan? Unveiling the New Face Behind North Korea’s Nuclear Ambitions

Choi Il-hwan has emerged as a key figure in North Korea's nuclear program, succeeding Hong Seung-moo amid leadership changes.

K-Beauty Revolution: Jenecell’s Stem Cell Skincare Launch in 2026

Jenecell launches a K-beauty skincare line, partnering with Helios for stem cell culture medium to enhance product performance and market reach.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Unlocking Cancer Treatment: How TXN12923 Targets ULK1 for Enhanced Drug Sensitivity

Txinno Bioscience to present TXN12923, a novel ULK1 targeted protein degrader, at AACR, aiming to enhance cancer treatment efficacy.

Coreline Soft Provides AI Lung Cancer Screening Solution to Charité University Hospital in Germany

Coreline Soft implements AI lung cancer screening solutions at Charité University Hospital, enhancing diagnostic efficiency and consistency.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

How Rasmotinib and PHI-501 Could Revolutionize Cancer Treatment: Insights from Bio Europe Spring 2026

Pharos iBio showcases its cancer treatments at Bio Europe Spring 2026, seeking global partnerships for Rasmotinib and PHI-501.

Nesuparib: A Game-Changer in Cancer Treatment? Key Findings from AACR 2026

Onconic Therapeutics' Nesuparib shows promising results against small cell lung and pancreatic cancers, highlighting its competitive edge.

New Breakthrough: HER2 Positive Stomach Cancer Treatment with Dual Targeted Therapy Shows 81% Tumor Size Reduction

A study reveals that combining trastuzumab deruxtecan and pertuzumab significantly reduces tumor size in HER2-positive gastric cancer.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Unlocking Treatment Potential: GI-102 and Pasritamig Clinical Trial Insights

GI Innovation has filed an IND application for a clinical trial on a combination therapy for metastatic prostate cancer in South Korea and the U.S.

Breakthrough Cancer Drug BAL0891: Key Findings to be Revealed at AACR 2026

SillaJen's cancer drug BAL0891 will be presented at the AACR 2026 conference, highlighting its effects on gastric and breast cancer models.

Lunit Scope: How AI Biomarkers Are Revolutionizing Cancer Treatment at AACR 2026

Lunit to present six AI biomarker studies at AACR 2026, showcasing advancements in cancer treatment and AI technology.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

Celltrion’s Ramucirumab and Infliximab: The Secrets Behind Their Dominance in Oceania’s Biopharmaceutical Market

Celltrion's cancer and autoimmune products are expanding market share in Australia and New Zealand, enhancing influence in Oceania.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.